Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.

ABSTRACT:

Background

Pediatric oncologists have begun to leverage tumor genetic profiling to match patients with targeted therapies. At the Memorial Sloan Kettering Cancer Center (MSKCC), we developed the Pediatric Molecular Tumor Board (PMTB) to track, integrate, and interpret clinical genomic profiling and potential targeted therapeutic recommendations.

Procedure

This retrospective case series includes all patients reviewed by the MSKCC PMTB from July 2014 to June 2015. Cases were submitted by treating oncologists and potential treatment recommendations were based upon the modified guidelines of the Oxford Centre for Evidence-Based Medicine.

Results

There were 41 presentations of 39 individual patients during the study period. Gliomas, acute myeloid leukemia, and neuroblastom

SUBMITTER: Ortiz MV 

PROVIDER: S-EPMC5429592 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature